CVD Predisposition Detection Kit Using Bisulfite Conversion and SNP Genotyping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for screening cardiovascular disease (CVD) are inefficient due to the obscuration of epigenetic signatures by gene-methylation interaction effects, limiting their clinical utility in predicting CVD.
Innovation Solution
A kit and method for determining the methylation status of CpG dinucleotides and genotype of single-nucleotide polymorphisms (SNPs) using specific nucleic acid primers, particularly for sites associated with the Transforming Growth Factor, Beta Receptor III (TGFBR3) gene and other genes, to predict CVD predisposition by bisulfite conversion and genotyping of biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If epigenetic techniques are applied to CVD detection, then the ability to detect certain disorders is improved, but the power of these methods is diminished due to gene×methylation interaction effects
Solution Approach 1:
The patent segments the complex gene×methylation interaction effects into separate detectable components by using specific primer sets that target either methylation status or SNP genotype independently. This allows each factor to be measured separately rather than being obscured by their interactions, resolving the contradiction between detection accuracy and clinical utility.
Solution Approach 2:
The patent introduces specific nucleic acid primers as intermediaries that facilitate the separate detection of methylation status and SNP genotype. These primers act as mediators that enable independent measurement of each factor, preventing the obscuration effect and maintaining both detection accuracy and clinical utility.
2Ease of operation
If screening techniques are simplified for clinical implementation, then ease of operation is improved, but efficiency is reduced
Solution Approach 1:
The patent creates a universal screening kit that can detect multiple CVD risk factors (methylation status and SNP genotype) using a single integrated system. The primer sets are designed to work together in a unified protocol, allowing clinicians to screen for multiple parameters simultaneously without requiring separate complex procedures, thus maintaining both ease of operation and screening efficiency.
3Measurement precision
If specific nucleic acid primers are used to detect methylation status and SNP genotype, then measurement precision is improved, but device complexity increases
Solution Approach 1:
The patent merges the detection of methylation status and SNP genotype into a single integrated kit containing coordinated primer sets. By combining these detection capabilities in one system with standardized protocols, the complexity is consolidated and managed rather than multiplied, allowing high measurement precision without proportionally increasing operational complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the ability to predict CVD predisposition by accurately detecting methylation and SNP status, improving clinical utility in diagnosing and treating CVD.
Implementation Method 1
A kit and method for determining the methylation status of CpG dinucleotides and genotype of single-nucleotide polymorphisms (SNPs) using specific nucleic acid primers, particularly for sites associated with the Transforming Growth Factor, Beta Receptor III (TGFBR3) gene and other genes, to predict CVD predisposition by bisulfite conversion and genotyping of biological samples.
Data Source
AI summary
Methods and compositions are provided for detecting a predisposition for cardiovascular disease in an individual.